David A. Cooney - Concepedia

Author

David A. Cooney

Also Known As

Cooney, D A, D A Cooney, D Cooney, D. A. COONEY, D. A. Cooney, D. Cooney, D.A. Cooney, DAVID A. COONEY, David A Cooney, David A. Cooney

190

Publications

6.5K

Citations

H-Index

133

Concepts

All Affiliations

National Cancer Institute National Institutes of Health St. Jude Children's Research Hospital

About

David A. Cooney is an author at National Cancer Institute specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	66	4.2K
2	Natural Sciences	21	26	1.4K
3	Engineering	5	5	116
4	Education	1	1	124
5	Health Sciences	1	1	15

David A. Cooney

100

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity David A. Cooney, Maha Dalal, Hiroaki Mitsuya, Biochemical Pharmacology MedicineHtlv-iii InfectivityAntiviral Drug DevelopmentAntiviral TherapyVirology	1986	322
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. Carlo Federico Perno, Robert Yarchoan, David A. Cooney, The Journal of Experimental Medicine Human Immunodeficiency VirusViral ProductionRelated CongenersHuman RetrovirusImmunology	1989	290
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. Carlo Federico Perno, Robert Yarchoan, David A. Cooney, The Journal of Experimental Medicine Several DideoxynucleosidesHuman Immunodeficiency VirusMedicineHuman RetrovirusRelated 2',3'-Dideoxynucleosides	1988	232
The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Philip S. Schein, David A. Cooney, M L Vernon PubMed Diabetes ManagementPharmaceutical ScienceAntitumor ActivityBiochemistryMedicine	1967	190
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. David A. Cooney, Neil R. Hartman, Carlo Federico Perno, Molecular Pharmacology	1988	160
Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity Gurpreet S. Ahluwalia, David A. Cooney, Hiroaki Mitsuya, Biochemical Pharmacology Molecular PharmacologyHiv InfectivityMedicineAntiviral Drug DevelopmentAntiviral Therapy	1987	147
Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide NSC 286193) Hiremagalur N. Jayaram, Robert L. Dion, Robert I. Glazer, Biochemical Pharmacology Medicinal ChemistryInitial StudiesBiochemistryNew Oncolytic ThiazoleNatural Sciences	1982	144
Bleomycin-induced interstitial pneumonia in dogs Robert W. Fleischman, John Baker, George R. Thompson, Thorax AntibioticsPneumothoraxSurgical PathologyDifferent DosagesVeterinary Science	1971	138
Consequences of IMP Dehydrogenase Inhibition, and its Relationship to Cancer and Apoptosis Hiremagalur N. Jayaram, Michael Grusch, David A. Cooney, Current Medicinal Chemistry	1999	134
cis-Dichlorodiammineplatinum(II) (NSC-119 875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice U. Schaeppi, Irwin A. Heyman, Robert W. Fleischman, Toxicology and Applied Pharmacology Preclinical Drug EvaluationIntravenous InjectionPharmacologyNsc-119 875Poisoning	1973	132

Page 1